Hem › Steatotisk leversjukdom › Georgia
Kliniska studier för Steatotisk leversjukdom i Georgia
8 studier för Steatotisk leversjukdom söker deltagare vid platser i Georgia.
Städer i Georgia
Officiell studietext (engelska)
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Southeast Clinical Research Center, Dalton
- Teak Research Consults, Lawrenceville
- Gastrointestinal Specialists of Georgia, Marietta
- och 1 fler
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Atlanta
- Akero Clinical Study Site, Gainesville
- Akero Clinical Study Site, Marietta
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 21 sep. 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- CenExel - iResearch, Decatur
- Gastrointestinal Specialists of Georgia, PC, Marietta
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 9 sep. 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Athens
- 89bio Clinical Study Site, Dalton
- 89bio Clinical Study Site, Marietta
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 3 sep. 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Athens
- 89bio Clinical Study Site, Atlanta
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 3 sep. 2026 · NCT06419374A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Atlanta
RekryterarFas 2
Ålder 18 till 70 · Alla kön · Uppdaterad 3 aug. 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Marietta
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 27 juli 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Marietta
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 8 juli 2026 · NCT06920043Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.